Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating in a report released on Thursday.
Several other equities research analysts have also commented on REGN. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 3rd. Canaccord Genuity set a $522.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. BMO Capital Markets set a $491.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, August 3rd. Citigroup raised their price objective on shares of Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. Finally, UBS reissued a “buy” rating and set a $535.00 price objective (up from $489.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 4th. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $467.84.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at $373.47 on Thursday. Regeneron Pharmaceuticals has a one year low of $340.09 and a one year high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The company has a market cap of $38,877.88, a price-to-earnings ratio of 31.33, a P/E/G ratio of 1.42 and a beta of 1.54.
In other news, SVP Robert E. Landry sold 663 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total value of $330,571.80. Following the sale, the senior vice president now owns 10,099 shares of the company’s stock, valued at $5,035,361.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the sale, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,352 shares of company stock worth $2,037,772. Insiders own 10.80% of the company’s stock.
Several large investors have recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after acquiring an additional 416,192 shares in the last quarter. BlackRock Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.7% during the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after buying an additional 41,406 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 2.9% during the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after buying an additional 148,962 shares in the last quarter. Harding Loevner LP boosted its holdings in Regeneron Pharmaceuticals by 589.2% during the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock worth $286,619,000 after buying an additional 3,131,966 shares in the last quarter. Finally, Artisan Partners Limited Partnership boosted its holdings in Regeneron Pharmaceuticals by 1.5% during the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after buying an additional 29,252 shares in the last quarter. 69.47% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/02/regeneron-pharmaceuticals-regn-lowered-to-c-at-thestreet.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.